Seaport Therapeutics Inc SPTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
-
Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
-
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
-
Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance
-
Seaport Therapeutics to Participate in September Investor Conferences
-
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
-
Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
-
Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference
Trading Information
- Previous Close Price
- $17.91
- Day Range
- $17.89–18.79
- 52-Week Range
- $14.85–28.38
- Bid/Ask
- $12.09 / $18.15
- Shares Outstanding
- 53.53M
- Market Cap
- $971.58M
- Volume/Avg
- 171,206 / 181,947
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.seaporttx.com
Valuation
|
Metric
|
SPTX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.30 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SPTX
|
|---|---|
Quick Ratio | 17.75 |
Current Ratio | 18.00 |
Interest Coverage | — |
Quick Ratio
SPTX
Profitability
|
Metric
|
SPTX
|
|---|---|
Return on Assets (Normalized) | −32.92% |
Return on Equity (Normalized) | −140.97% |
Return on Invested Capital (Normalized) | −142.55% |
Return on Assets
SPTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|vV#%^zL | LOCK|s%p^T | $129B | |||
| Moderna Inc
MRNA
| LOCK|NHH<f>r | LOCK|@d> | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|&<?f!K% | LOCK|s@Xz | $77B | |||
| argenx SE ADR
ARGX
| LOCK|<>GsFLg | LOCK|pj | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|!?M%<W | LOCK|^R< | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|!n!Yth | LOCK|!#!< | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|@^z&Vm> | LOCK|@j<# | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|m&&V&^m | LOCK|Y#? | $24B | |||
| Incyte Corp
INCY
| LOCK|#Q^$L$ | LOCK|!vS | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|##W>!> | LOCK|g@T | $14B |
United States